David S. Boyer, MD

Articles by David S. Boyer, MD

Q&A: Evolving approaches to geographic atrophy management

ByDavid S. Boyer, MD,Matt Hoffman

January 17th 2026

Optigo: Lead anti-VEGF program advancing toward IND-enabling studies

ByDavid S. Boyer, MD, Arshad M. Khanani, MD, MA, FASRS,Sheryl Stevenson

November 8th 2025

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Q&A: David S. Boyer, MD, on the suprachordial delivery of gene therapy

ByDavid S. Boyer, MD,Sydney M Crago

June 5th 2025

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, offering reduced risks and improved outcomes.

David S. Boyer, MD

Articles by David S. Boyer, MD

Q&A: Evolving approaches to geographic atrophy management

Optigo: Lead anti-VEGF program advancing toward IND-enabling studies

Q&A: David S. Boyer, MD, on the suprachordial delivery of gene therapy

Latest Updated Articles

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Metformin use associated with reduced incidence of intermediate AMD

MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio

Last year in glaucoma at EnVision Summit 2025

Looking back at the 2025 EnVision Summit

China's NMPA approves ZEISS ARTEVO 750 and ARTEVO 850 ophthalmic surgical microscopes for clinical use